
PV-Works is a single-tenant, web-delivered ICSR case-processing database and adverse-event workflow engine, hosted as SaaS (PV247) or deployed on-premises. It targets mid-sized pharma, biotech, and animal-health companies, CROs, and competent authorities. A packaged "Essentials" tier offers a fast-start, low-configuration footprint, alongside a free Starter trial that converts to production.
PV-Works is a product of Ennov (Ennov PV, the UK pharmacovigilance arm). The original developer was Assured Information Systems Ltd. (AIS), based near Cambridge, UK. AIS joined the Ennov Group in July 2014 and is now referred to as Ennov PV. Two similarly-named companies are not PV-Works vendors: Online Business Applications (OBA) built a different product, IRMS, and was acquired by Anju Software in June 2016; Foresight Group International AG (Zug, Switzerland) is an Oracle Channel Partner for Argus.
PV-Works manages adverse events from clinical trials, spontaneous post-marketing reports, medical inquiries, and product quality complaints across pharma, biological, medical-device, and veterinary product lines. The system pairs structured case-entry templates with an optional purpose-built workflow engine, integrated MedDRA coding, configurable validation/cross-field checks, duplicate detection, automated letter generation, and a built-in query engine that surfaces case work-lists and compliance metrics.
PV-Works is offered in three packaged tiers: PV247 Essentials (fixed configuration, hosted), PV247 Starter (free trial that converts to production), and Enterprise (configurable, on-premises or hosted). The wider Ennov PV Suite includes companion modules PV-Works Human, PV-Works Vet, PV-Analyzer (statistical analysis and data mining), PV-Signal Manager (signal detection workflow), PV-Entry (high-volume intake/triage front end), PV-Express (lightweight intake form), and Doc for Pharmacovigilance.
Ennov positions PV-Works at small-to-mid-sized sponsors, CROs, animal-health companies, and national PV centres.
PV-Works Human (human pharma/biotech ICSRs) and PV-Works Vet (veterinary ICSRs supporting VICH HL7 XML and EU Veterinary XML). Three packaged tiers: PV247 Essentials, PV247 Starter (free trial converting to production), and Enterprise (configurable on-premises or hosted).
Deployment: two options — on-premises (single-tenant deployment behind customer firewall) and cloud-hosted SaaS (PV247). The vendor states customers can switch between deployment models at any time, and markets "single tenancy" as a deployment property regardless of hosting location. Cloud provider regions are not publicly stated. Ennov PV is headquartered near Cambridge, UK, with hosting historically EU-based. Sovereign cloud (EU/China/India/GovCloud) status: unknown.
Architecture: older AIS-era PV-Works was a Delphi-Windows client against an Oracle relational backend, typically delivered via Citrix in global enterprise deployments. Current marketing positions the platform as "100% web-based" within the broader Ennov platform. PV-Entry/PV-Express are explicitly browser- and mobile-optimised. Browser-version minimums, SSO/SAML/OIDC support, and named identity-provider integrations (AzureAD, Okta) are not publicly documented.
APIs: REST API documented as integration mechanism for PV-Signal Manager. GraphQL, webhooks, rate limits, SDKs, and named pre-built connectors (Veeva CRM, IRMS, Salesforce) are not publicly documented.
Data standards supported (explicit): ICH E2B(R2), E2B(R3), EU Veterinary XML, VICH HL7 XML (FDA CVM), eMDR, MedDRA. WHO Drug Dictionary, HL7 FHIR, and CDISC are unknown and not publicly claimed.
Pricing transparency: no public price list, and no starting price is published for PV247 or Enterprise licensing.
Subscription-based pricing applies to PV247 SaaS, sold in packaged tiers: Starter, Essentials, and Enterprise. Essentials has fixed configuration (up to 7 Market Authorisation Holders, unlimited Clinical Trial Sponsors, single manufacturer-address per country). Enterprise allows custom queries, reports, and configuration. On-premises perpetual licensing is offered for Enterprise deployments.
The free Starter trial converts to production without re-platforming. The Starter account is fully functional with no usage limits and starts immediately on a self-service basis.
Reported deal sizes by customer segment, minimum commitments, setup fees, and validation-support fees are not publicly disclosed.
Vendor publishes "4 Months" as an impact statistic in a 2026 PV vendor-change case study, implying complete migration from another safety system can be completed in roughly that window for at least one customer. Vendor reports 98.5% of projects delivered on time and within budget, self-reported and not independently verified.
Hosting, implementation, training, and support are each marketed as discrete service lines on the Ennov Services page, implying they are priced separately rather than bundled into the licence. Validation-support fees are not publicly itemised.
Migration: PV-Works can import any technically valid E2B XML file directly into the case database, and follow-up cases can also be received electronically. Named migrators for Argus or ARISg legacy systems are not publicly documented, though E2B-based migration is the de-facto industry path. Excel/CSV import paths are not explicitly published.
The 2026 vendor case study titled "From Vendor Frustration to Compliance Confidence" is vendor-published and self-selected. Independent commentary notes that validation overhead for E2B-gateway use can be perceived as burdensome relative to manual EVWeb submission.
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
Independent commentary describes PV-Works as a viable mid-market safety-database choice, noting that major safety databases generally "offer the same basic functionality and data handling capabilities to support compliance" and that implementation quality affects outcomes more than the choice of database. Independent technical reviews describe PV-Works' integrated MedDRA browser, with PT-and-synonym search, and its rapid-coding tool as user-friendly. Independent commentary identifies veterinary PV as a strength of the product.
Public, attributable user complaints on PV-Works are sparse, and the product has a limited public review footprint. Buyers rely on reference calls as a result. Legacy architecture from the Delphi/Citrix era and a multi-year transition to a "100% web-based" Ennov platform mean whether a given deployment is fully web-native or a thin-client wrapper is not stated in vendor materials. No published GAMP 5 categorisation. No SOC 2 Type II. No pre-validated multi-tenant SaaS claim. No native PMDA E2B or J-Drug coding is publicly claimed.
Share your experience with Ennov PV-Works anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackJump to section